Theravance Biopharma, Inc. 8K

Theravance Biopharma, Inc. reported Q2 2026 results and announced details of its pending acquisition by Zymeworks Inc. for $17.00 per share in cash plus a CVR tied to future ampreloxetine monetization, expected to close in the second half of 2026 subject to shareholder approval.

On August 10, 2026, Theravance Biopharma, Inc. reported its second quarter 2026 financial results and provided a corporate update highlighting a pending acquisition by Zymeworks Inc. under a definitive agreement signed on June 29, 2026, pursuant to which Zymeworks will acquire Theravance for $17.00 per share in cash plus a contingent value right for 80% of net proceeds from any future monetization of ampreloxetine over ten years. The company noted that the transaction is expected to close in the second half of 2026, subject to shareholder approval and customary closing conditions, and detailed related restructuring and transaction costs, including $6.1 million of transaction-related expenses and substantial cost reductions from an ongoing organizational restructuring. Alongside the M&A update, Theravance reported Q2 2026 Viatris collaboration revenue of $20.7 million (up 11% year-over-year), implied 35% YUPELRI net sales share of $24.7 million, a quarter-end cash balance of $387.7 million with no debt, and a shift from prior-year net income to a GAAP net loss driven by the absence of a one-time 2025 gain on TRELEGY royalty assets, while posting positive non-GAAP net income from operations.

Filing Facts

CIK

1583107

Ticker

TBPH

Form

8K

Source Type

fda

Accession

0001104659-26-093066

Alert Tier

8